Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
* Shares of Iovance Biotherapeutics rise 27.5% to $14, their highest level in more than two years * Co raises FY26 revenue outlook to $410 mln-$420 mln, from a prior forecast of $350 mln-$370 mln * "Our record second quarter and sustained demand for Amtagvi and Proleukin led us to raise our full year 2026 total revenue
Iovance Biotherapeutics lifted full-year 2026 total revenue guidance to $410 million-$420 million from $350 million-$370 million, citing strong U.S. demand for Amtagvi and Proleukin. Second-quarter 2026 total product revenue hit a record $99.3 million.